nrti + nnrti + lopinavir + ritonavir

This is a combination antiretroviral therapy regimen for HIV treatment consisting of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and the fixed-dose combination of lopinavir/ritonavir (Kaletra). This multi-class approach targets HIV through different mechanisms to effectively suppress viral replication and prevent the development of resistance. The lopinavir/ritonavir component contains two protease inhibitors, with ritonavir primarily functioning as a pharmacokinetic booster that slows the breakdown of lopinavir in the liver, allowing it to maintain therapeutic levels.